While we observed no differences in OS, CVD risk, or clinical remission rates by CHIP status in patients with RA in multivariable models, the relative efficacy of IL-1β inhibition in RA subtypes by CHIP status could be tested in future clinical trials for personalized therapy. The gene discussed is IL1B; the disease is rheumatoid arthritis.